{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["AG","mFOLFIRINOX"]],"indication":"resectable pancreatic cancer","name":"CISPD-1","nct_id":"NCT03750669","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cispd-1-nct03750669. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive the sequential neoadjuvant chemotherapy of AG regimen (nab-paclitaxel plus gemcitabine) and mFOLFIRINOX before resection.","label":"Neoadjuvant Chemotherapy","type":"EXPERIMENTAL"},{"description":"Patients receive surgical treatment without any neoadjuvant treatments.","label":"control","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2025-03-01","type":"ACTUAL"},"conditions":["Pancreatic Adenocarcinoma Resectable","Neoadjuvant Chemotherapy"],"enrollment":{"count":324,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AG regimen","otherNames":["Nab-paclitaxel and Gemcitabine"],"type":"DRUG"},{"name":"mFolfirinox","otherNames":["Folic acid, 5- fluorouracil, irinotecan and oxaliplatin"],"type":"DRUG"}],"last_update":"2025-05-13","lead_sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","official_title":"Sequential Use of Nab-paclitaxel Plus Gemcitabine and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer: A Randomized Control Study","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-11-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"event-free survival (EFS)","timeFrame":"From randomization to any of the following events: progression of disease that precludes resection, local or distant recurrence, or death due to any cause, whichever occurs first. Up to approximately 60 months."}],"references":[],"start_date":{"date":"2018-10-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT03750669"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cispd-1-nct03750669"}